Glyphosate is the active ingredient in many herbicides, including Roundup®, and has been widely used in agriculture, landscaping, forestry, and residential weed control since the 1970s. People may be exposed while mixing or applying glyphosate-based herbicides, working in agricultural settings, or through environmental contact. Researchers have spent decades studying whether long-term glyphosate exposure may be associated with an increased risk of certain health conditions, particularly non-Hodgkin lymphoma. Although scientific and regulatory organizations have reached different conclusions, research and legal proceedings continue to evolve.
Glyphosate exposure can occur in occupational, agricultural, residential, and environmental settings. The amount and frequency of exposure varies considerably depending on how glyphosate-based herbicides are used, whether protective equipment is worn, and how often someone comes into contact with treated areas.
Glyphosate is used in a variety of herbicide formulations designed to control broadleaf weeds and grasses. Products containing glyphosate have been used on farms, commercial properties, public spaces, and residential landscapes for decades. Exposure may occur while mixing, spraying, or handling glyphosate-based products, particularly when appropriate protective measures are not followed. Researchers also continue studying differences between glyphosate itself and complete herbicide formulations that contain additional ingredients.
Many glyphosate lawsuits allege that manufacturers failed to adequately warn consumers about potential health risks associated with long-term exposure. Litigation has also focused on whether product labeling, safety communications, scientific reporting, and regulatory submissions accurately reflected the available evidence as scientific understanding evolved. These issues continue to be examined through ongoing litigation and scientific review.
People who regularly mix, spray, or apply glyphosate-based herbicides may experience greater cumulative exposure than the general population. Occupational exposure has been studied among farmers, groundskeepers, landscapers, agricultural workers, pesticide applicators, and others who routinely work with herbicides. Environmental exposure may also occur through contact with treated vegetation or drift during application, although exposure levels generally differ from occupational settings.
Researchers continue studying why some individuals may be more susceptible to developing disease after environmental or occupational exposures than others. Factors such as genetics, immune system function, age, duration of exposure, and cumulative lifetime exposure are all being evaluated. Having one or more risk factors does not mean an individual will develop non-Hodgkin lymphoma, but these variables are often considered in epidemiological research.
Exposure to herbicides is not limited to glyphosate. Researchers have also studied other widely used herbicides, including paraquat, for potential associations with serious health conditions through different biological mechanisms.
Glyphosate has been the subject of extensive scientific research for decades, making it one of the most studied herbicides in the world. Researchers have examined potential links between glyphosate exposure and cancer, particularly non-Hodgkin lymphoma, while regulatory agencies have reviewed many of the same studies and, in some cases, reached different conclusions.
Research on glyphosate continues to expand through epidemiological studies, laboratory research, and reviews of occupational exposures. In 2015, the International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" (Group 2A) based largely on evidence related to non-Hodgkin lymphoma. More recent reviews, including a 2025 analysis published in Clinical Lymphoma, Myeloma & Leukemia, concluded that newer epidemiologic, animal, and mechanistic studies continue to support further evaluation of a possible association between glyphosate-based herbicides and non-Hodgkin lymphoma.
In late 2025, one of the most frequently cited papers supporting glyphosate's safety was formally retracted after the journal found it relied exclusively on unpublished Monsanto studies and cited concerns about undisclosed company involvement in its preparation. The retraction has renewed discussion about scientific transparency and reinforces why glyphosate continues to be the subject of ongoing independent research and regulatory review.
Glyphosate is the most widely used herbicide in the world and has been applied to hundreds of millions of acres of farmland in the United States since its introduction in the 1970s. Due to its widespread agricultural, commercial, and residential use, millions of workers and consumers have experienced some level of glyphosate exposure over the past several decades.
There is no medical treatment that removes glyphosate from the body after exposure. Current research instead focuses on improving exposure assessment, biomonitoring, and understanding the biological mechanisms that may contribute to disease. At the same time, medical advances continue for non-Hodgkin lymphoma, including targeted therapies, immunotherapy, CAR T-cell therapy, precision medicine, and earlier diagnostic approaches that may improve treatment outcomes.
Research on glyphosate exposure is supported by organizations including the National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), the National Toxicology Program (NTP), and academic research institutions around the world. Clinical trials related to non-Hodgkin lymphoma continue to evaluate new immunotherapies, targeted therapies, cellular therapies, and supportive care strategies. Individuals interested in clinical trials for non-Hodgkin lymphoma treatment can search ClinicalTrials.gov, the National Cancer Institute, or major cancer centers while discussing treatment options with their healthcare team.
Although glyphosate-based herbicides remain widely used, individuals may be able to reduce unnecessary exposure by following product directions, using appropriate protective equipment, and handling herbicides safely.
People who use glyphosate-based herbicides should carefully read and follow product labeling, wear any recommended personal protective equipment, avoid unnecessary skin contact or inhalation during application, and store herbicides safely away from children and pets. Individuals who frequently work with herbicides may also benefit from changing clothing and washing exposed skin after use to help minimize repeated exposure.
Glyphosate exposure does not cause immediate symptoms that indicate whether someone has developed a serious illness. However, individuals experiencing persistent swollen lymph nodes, unexplained weight loss, recurring fevers, drenching night sweats, unusual fatigue, or other symptoms that do not improve should seek medical evaluation. These symptoms can have many possible causes, but persistent or worsening changes warrant discussion with a healthcare provider.
Glyphosate continues to be reviewed by regulatory agencies around the world as new scientific evidence becomes available. The EPA has stated that glyphosate is “not likely to be carcinogenic to humans” when used according to label directions, while the International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” in 2015. Glyphosate remains the subject of scientific debate, regulatory scrutiny, and ongoing litigation.
Glyphosate products are regulated as pesticides and must meet federal labeling and registration requirements before they can be sold in the United States. Manufacturers continue updating product labels, safety information, and handling instructions as regulatory requirements evolve. At the same time, scientific debate, regulatory review, and litigation continue to shape discussions about product safety, warning labels, and the evidence used to evaluate potential health risks.
Individuals diagnosed with non-Hodgkin lymphoma after significant glyphosate exposure may wish to better understand their legal options. Whether someone may have a legal claim depends on many factors, including the nature and duration of exposure, medical diagnosis, available evidence, and the laws of the state where a claim is filed.
Every glyphosate-related claim is evaluated on its own facts. Attorneys reviewing these cases may consider an individual's diagnosis, occupational or residential exposure history, the types of glyphosate-based herbicides used, medical records, and other documentation that helps establish when and how exposure occurred.
Depending on the circumstances, individuals pursuing glyphosate-related claims may seek compensation for medical expenses, future medical care, lost wages, reduced earning capacity, pain and suffering, caregiving costs, and, in some cases, wrongful death damages. The compensation available in any case depends on the specific facts, applicable law, and supporting evidence.
The deadline for filing a glyphosate-related claim varies by state and may depend on when an individual was diagnosed or reasonably became aware of a possible connection between non-Hodgkin lymphoma and prior glyphosate exposure.
Relevant records may include medical records, pathology reports confirming a non-Hodgkin lymphoma diagnosis, employment history, pesticide applicator records, purchase receipts, photographs of products used, worksite information, and other documentation showing how, where, and how often glyphosate-based herbicides were used.
Glyphosate litigation has involved tens of thousands of lawsuits alleging that long-term exposure to Roundup® and other glyphosate-based herbicides contributed to non-Hodgkin lymphoma. Many cases have centered on allegations involving product warnings, scientific evidence, regulatory decisions, and whether consumers and workers received adequate information about potential risks.
Since the first Roundup trials began in 2018, several juries have returned substantial verdicts in favor of plaintiffs, while other cases have resulted in defense verdicts, settlements, appeals, or dismissal. Bayer, which acquired Monsanto in 2018, has agreed to resolve many Roundup claims through multi-billion-dollar settlement programs while continuing to defend additional lawsuits. In June 2026, the U.S. Supreme Court overturned a Missouri jury verdict in a Roundup case, a decision expected to affect thousands of pending lawsuits, while litigation continues in courts across the country.
© 2026, Injury Info. All rights reserved.